Showing 5311-5320 of 5621 results for "".
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- MacuLogix Relocates to Larger Headquarters in Harrisburg, Pennsylvania to Accommodate Growthhttps://modernod.com/news/maculogix-relocates-to-larger-headquarters-in-harrisburg-pennsylvania-to-accommodate-growth/2476286/MacuLogix relocated its headquarters from Middletown, PA, to Harrisburg as the company has grown from 12 to 65 employees in the past 3 years, including 25 home office employees supporting its national field-based sale
- UnitedHealthcare Vision Plans Rank Highest in Customer Satisfaction in J.D. Power Reporthttps://modernod.com/news/unitedhealthcare-vision-plans-rank-highest-in-customer-satisfaction-in-j-d-power-report/2476287/UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nation’s vision carriers, according to the J.D. Power 2018 Vision Plan Satisfaction Report. This marks the fifth time in 6 years that UnitedHealthcare Vision has earned the highest ranking among vision plans.
- New Medscape Report Finds More Than One in Three Doctors are Burned Outhttps://modernod.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/Burnout and depression are having a significant effect on the global medical community, as demonstrated by Medscape’s Global Physicians’ Burnout and Lifestyle Comparisons report. Nearly 20,000 doctors in six countries (France,
- Eyenovia Confirms Expanded MicroProst Phase 3 Indication to Enroll Broad Patient Population for IOP Loweringhttps://modernod.com/news/eyenovia-confirms-expanded-microprost-phase-3-indication-to-enroll-broad-patient-population-for-iop-lowering/2476294/Eyenovia confirmed a broad patient population for its phase 3 MicroProst program (microdose latanoprost with Optejet delivery) for the lowering of IOP. Following discussions with the FDA, the study population will include chronic a
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- Topcon Healthcare Solutions and Oculo Form Global Partnershiphttps://modernod.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/Topcon Healthcare Solutions (THS) and Oculo, a technology provider in clinical communications based out of Melbourne, Australia, have announced a new partnership that will combine the strengths of their Topcon Harmony and Oculo eye care platforms. Financial terms of the deal were not disc